Market research
CPH1.F Histogen Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 2.7
- Dividend yield
- 0.0%
- Beta
- -0.17
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 2.7
- Dividend yield
- 0.0%
- Beta
- -0.17
About
About Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Research context
Histogen Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CPH1.F discussion.
5 years, 7 months ago
Histogen Inc is currently in a long term downtrend where the price is trading 24.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Histogen Inc's total revenue sank by 69.4% to $478K since the same quarter in the previous year.
Its net income has dropped by 51.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 141.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Histogen Inc gets an overall score of 1/5.